期刊文献+

HIV-1 CN54 Pol P51抗原高效表达、纯化、复性及在抗体检测中的应用 被引量:2

Expression, purification and renaturation of Pol P51 antigen of HIV-1 strain CN54 and its application in antibody detection
原文传递
导出
摘要 为获得可溶性高纯度HIV-1中国株CN54PolP51抗原,将携带CN54polp51基因的重组质粒pTHioHisA51转化大肠杆菌BL21codonplus-RIL,用IPTG进行诱导表达。用Chelating SepharoseFF-Ni亲和层析柱及DEAE Sepharose Fast Flow阴离子交换层析柱纯化目的蛋白,采用透析复性法得到可溶性抗原,Western blotting检测目的蛋白。用纯化的P51抗原蛋白标记辣根过氧化物酶及包被酶标板进行双抗原夹心法ELISA检测。结果显示P51以包涵体的形式表达,表达量占菌体总蛋白的50%,经两步层析和透析复性,目的蛋白纯度大于95%。Western blotting和双抗原夹心法ELISA检测均显示了良好的灵敏度和特异性。本研究可以为HIV-1疫苗研究和开发检测试剂提供支持。 To obtain the pure and soluble P51 antigen of HIV-1 strain CN54, we transformed the Escherichia. coli strain BL21 codonplus-RIL with recombinant plasmid pTHioHisA51 which carries a gene encoding the Polymerase (Pol) P51 antigen of HIV-1 CN54 formerly, and induced protein expression by IPTG. We purified the recombinant protein with Chelating Sepharose FF-Ni and DEAE-Sepharose FF column chromatography, then renatured the recombinant protein by dialyzation. Purified protein was identified by Western blotting. We labeled and coated antigen P51 in a dual-antigen sandwich system, and tested it with serum samples from HIV-infected individuals. The results showed that P51 was expressed as inclusion body, and represented about 50% of total cellular protein. After purification and renaturation, the purity of P51 was up to 95%. Western blotting and sandwich ELISA demonstrated that recombinant P51 had good anti-HIV antibody specificity and sensitivity. The results suggested that recombinant HIV-1 P51 can be prepared as diagnostic reagent, and provides valuable support for HIV-1 detection and vaccine research.
出处 《生物工程学报》 CAS CSCD 北大核心 2010年第2期201-206,共6页 Chinese Journal of Biotechnology
基金 国家十一五科技重大专项(Nos.2008ZX1001-1010 2009ZX10004-713)资助~~
关键词 HIV-1CN54 逆转录酶P51 纯化 复性 抗体检测 HIV-1 CN54 reverse transcriptase P51 purification renaturation antibody detection
  • 相关文献

参考文献17

  • 1Tasara T, Amacker M, Hubscher U, et al. Intramolecular chimeras of the p51 subunit between HIV-1 and FIV reverse transcriptases suggest a stabilizing function for the P66 subunit in the heterodimeric enzyme. Bioehemistry, 1999, 38: 1633-1642. 被引量:1
  • 2Cabodevilla JF, Odriozola L, Santiago E, et al. Factors affecting the dimerization of the P66 form of HIV-1 reverse transeriptase. Eur J Biochem, 2001, 268(5): 1163-1172. 被引量:1
  • 3黄祯祥主编..医学病毒学基础及实验技术[M].北京:科学出版社,1990:1002.
  • 4杨彩霞,傅继华,毕振强,张静,尤向东,苏生利,林琳.HIV-1感染者免疫学及血清学指标检测[J].中国公共卫生,2008,24(6):695-696. 被引量:9
  • 5DeVico AL, Veronese FD, Lee SL, et al. High prevalence of serum antibodies to reverse transcriptase in HIV-1- infected individuals. AIDS Res Hum Retrovir, 1988, 4(1): 17-22. 被引量:1
  • 6瞿小旺,杨再清,邵一鸣,等.中国株CN54HIV-1 Pol P66/P51在大肠杆菌中的表达与纯化.华中农业大学,2004. 被引量:1
  • 7Vallejo LF, Rinas U. Strategy for the recovery of active protein through refolding of bacterial inclusion body proteins. Microb Cell Fact, 2004, 3:11. 被引量:1
  • 8Gavit P, Better M. Production of antifungal recombinant peptides in Escherichia coli. J Biotechnol, 2000, 79(2): 127-136. 被引量:1
  • 9Patra AK, Mukhopadhyay R, Muhhija R, et al. Optimization of inclusion body solubilization and renaturation of recombinant human growth hormone from Escherichia coli. Protein Expr Purif, 2000, 18(2): 182-192. 被引量:1
  • 10傅晶晶,孙静,陈佩,霍烛,范文玲,郝彦玲,刘勇.HIV-1 Gag蛋白在大肠杆菌表达系统中诱导和纯化条件的优化[J].生物工程学报,2008,24(7):1306-1311. 被引量:3

二级参考文献42

  • 1尤向东,傅继华,王同展,苏生利,李小娟,吕翠霞.2004年山东省艾滋病确认实验室检测结果分析[J].中国公共卫生,2005,21(11):1383-1384. 被引量:5
  • 2蒋静,赵丽辉,于湘晖,姜春来,吴永革,貌盼勇,李惟,孔维.HIV-1嵌合抗原的纯化及免疫原性分析[J].高等学校化学学报,2005,26(12):2259-2263. 被引量:2
  • 3罗曼,关怡新,姚善泾.大肠杆菌二硫键形成蛋白A(DsbA)研究进展[J].生物工程学报,2007,23(1):7-15. 被引量:5
  • 4Bongertz V,Guimaraes ML,Soares-Da-Costa MF,et al.Anti-HIV-1 seroreactivity and HIV transmission route.J Clin Virol,1999,12(1):27-36. 被引量:1
  • 5Vallejo LF, Rinas U. Stratgy for recovery of active protein though refoldlng of baeterial inclusion body proteins. Microb Cell Fact, 2004, 3:11. 被引量:1
  • 6Gavit P, Better M. Production of antifungal recombinant peptides in Escherlchla coli. J Biotechnol, 2000, 79(2): 127-136. 被引量:1
  • 7Patra AK, Mukhopadhyay R, Muhhija R, et al. Optimization of inclusion body solubilization and renaturation of recombinant human growth hormone from Escherichia coli. Protein Expr Purif, 2000, 18 (2): 182-192. 被引量:1
  • 8Singh SM, Panda AK. Solubilization and refolding of bacterial inclusion body proteins. J Biosci Bioeng, 2005, 99(4): 303-310. 被引量:1
  • 9Galli RA,Castriciano S, Fearon M, et al. Performance characteristics of recombinant enzyme immunoassay to detect antibodies to human immunodeficiency virus type 1 (HIV-1) and HIV-2 and to measure early antibody responses in seroconverting patients.J Clin Microbiol,1996,34:999-1002. 被引量:1
  • 10Gaines H,Sydow M,Parry JV,et al.Detection of immunoglublin M antibody in primary human immunodeficiency virus infection.AIDS,1988,2:13-15. 被引量:1

共引文献22

同被引文献17

  • 1任莉,仇超,黄相刚,潘翔,徐建青,邵一鸣.HIV-1 B'亚型gag-env融合基因的DNA疫苗构建和免疫原性分析[J].中华微生物学和免疫学杂志,2006,26(7):654-658. 被引量:3
  • 2邵一鸣,罗夫·伟格拿,汉思·渥夫.HIV-1亚型间(C/B^*)基因组和其用途:中国,CN1423698[P].2003-6-11. 被引量:1
  • 3BURGERS WA, VAN HARMELEN JH, SHEPHARD E, et al. Design and preclinical evaluation of a multigene human immunod- eficiency virus type 1 subtype C DNA vaccine for clinical trial [J]. J Gen Virol,2006,87 (Pt2) :399 -410. 被引量:1
  • 4WALKER LE, VANG L, SHEN X,et al. Design and preclinical development of a recombinant protein and DNA plasmid mixed format vaccine to deliver HIV-derived T-lymphocyte epitopes [ J ]. Vaccine ,2009,27 ( 50 ) :7087 - 7095. 被引量:1
  • 5SNODIN DJ,RYLE PR. Understanding and applying regulatory guidance on the nonclinical development of biotechnology-derived pharmaceuticals[ J]. Bio Drugs ,2006,20( 1 ) :25 - 52. 被引量:1
  • 6CORBETT M,BOGERS WM, HEENEY JL,et al. Aerosol immu- nization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic [ J ]. Proc Natl Acad Sci, 2008, 105 ( 6 ) : 2046 - 2051. 被引量:1
  • 7HUO Y,LI B,ZHANG Y,et al. Pre-clinical safety evaluation of heat shock protein 65-MUC1 peptide fusion protein [ J]. Regul Toxicol Pharmacol,2007,49 ( 1 ) :63 -74. 被引量:1
  • 8GHIRARDELLO A,VILLALTA D, MOROZZI G,et al. Diagnos- tic accuracy of currently available anti-double-stranded DNA anti- body assays. An Italian multicentre study[ J]. Clin Exp Rheuma- tol,2011,29( 1 ) :50 - 56. 被引量:1
  • 9BAHARI MH, MAHMOUDI M, AZEMI A,et al. Early diagnosis of systemic lupus erythmatosus using ANN models of dsDNA binding antibody sequence data [ J ]. Bioinformation, 2010, 5 (2) :58 -61. 被引量:1
  • 10Burgers W A, Van Harmelen J H, Shephard E, et al. De- sign and preclinical evaluation of a multigene human immuno- deficiency virus type 1 subtype C DNA vaccine for clinical tri- al [J] . J Gen Virol, 2006, 87 (Pt2): 399-410. 被引量:1

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部